Shandong Boshan Pharmaceutical Co., Ltd.

Primary Objective: This study aims to investigate the pharmacokinetic characteristics of a single fasting administration of loxoprofen sodium patches (100 mg/patch (10 cm × 14 cm)) manufactured by Nanjing Jiuxiao Pharmaceutical Co., Ltd. in healthy subjects. Loxoprofen sodium patches (Lesong®, 100 mg/patch (10 cm × 14 cm)) certified by LEAD CHEMICAL CO., LTD. were used as the reference formulation. The pharmacokinetic parameters Cmax, AUC0-t, and AUC0-∞ of the two formulations were compared to evaluate their bioequivalence in humans. Secondary Objectives: 1) To evaluate the safety of the test formulation and the reference formulation in healthy subjects; 2) To evaluate the adhesion and skin irritation of the test formulation and the reference formulation during administration in healthy subjects.

Main research purpose: According to the relevant provisions of bioequivalence test, SANDOZ INC is the licensee of Perphenazine Tablets (trade name: PERPHENAZINE®, specification: 4mg) as the reference preparation, and the test preparation Perphenazine Tablets (specification: 4mg) produced and provided by Beijing Jingfeng Pharmaceutical (Shandong) Co., Ltd. is used for fasting and postprandial human bioequivalence test, to compare whether the absorption rate and degree of the drug in the test preparation are within the acceptable range with the reference preparation, and to evaluate the bioequivalence of the two preparations under fasting and postprandial administration conditions. Secondary research purpose: To observe the safety of oral administration of the test preparation Perphenazine Tablets (specification: 4mg) and the reference preparation Perphenazine Tablets (trade name: PERPHENAZINE®, specification: 4mg) by healthy volunteers.

Primary objective: To evaluate the bioequivalence of the two preparations in Chinese healthy subjects in the fasting and postprandial states, using the benzhexol hydrochloride tablets (specification: 2 mg) of Watson Laboratories Inc as the reference preparation and the benzhexol hydrochloride tablets (specification: 2 mg) developed by Beijing Jingfeng Pharmaceutical (Shandong) Co., Ltd. as the test preparation. Secondary objective: To observe the safety of the test preparation and the reference preparation in Chinese healthy subjects.